Literature DB >> 40887

Antihypertensive efficacy of a new long acting hydralazine like vasodilator, ISF 2469 in combination with a betablocker and a diuretic.

P van Brummelen, F R Bühler, W Kiowski, P Bolli, O Bertel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 40887

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN： 0340-0026


× No keyword cloud information.
  10 in total

1.  Cadralazine versus prazosin as second-step treatment in hypertensive patients on beta-blockers: a randomized multicentre study. The Italian Multicentre Study Group.

Authors:  S Caponnetto; E Valvo; P Mocarelli; D Alberti; S Savonitto
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Studies on the metabolism of cadralazine in rat.

Authors:  L Simonotti; M Zanol; F Parravicini; G Pifferi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

3.  Human pharmacokinetics of cadralazine: a new vasodilator.

Authors:  S A Hauffe; J P Dubois; P R Imhof
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jul-Sep       Impact factor: 2.441

Review 4.  Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  D McTavish; R A Young; S P Clissold
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

5.  Disposition and pharmacokinetics of cadralazine and individual metabolites in man.

Authors:  H Schütz; J W Faigle; W Küng; W Theobald
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

6.  Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics.

Authors:  B Persson; G Granerus; M Wysocki; T Hedner; O K Andersson
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Cadralazine (ISF 2469): dose-related antihypertensive activity after single oral administration to patients.

Authors:  M Catalano; J Parini; A Libretti
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  [14C]cadralazine: absorption, distribution and excretion in rat and dog.

Authors:  G Bonardi; E Rossi; M Pellegatti
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983       Impact factor: 2.441

9.  Cadralazine and chlorthalidone as a second-step drug with atenolol in hypertensive patients: differences in blood pressure control during exercise.

Authors:  F V Costa; C Borghi; A Mussi; E Ambrosioni
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily.

Authors:  J F Marichal; P Brunel; J B Lecaillon; J Godbillon; B Faller; P Brignon; J Ménard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.